| Name | Title | Contact Details |
|---|
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
At Nestlé Health Science, we’re advancing nutritional therapy to change the approach of managing your health. Behind our pioneering company are people who are driving breakthroughs and innovating for impact. Here, you have the chance to change the course of health and your career. Our people are exploring new territory and breaking new ground in areas such as GI, critical care, surgery, oncology, healthy ageing, food allergy, obesity, brain health and pediatrics. They are changing the way doctors think about meeting the nutritional needs of patients, and the way patients and consumers manage their own health. They know the faces, hear the stories and celebrate the successes of people who had their lives transformed thanks to Nestlé Health Science solutions. Be part of a journey that changes the course of health.
Regenerative Processing Plant is a biotechnology company that manufactures various stem cell stimulants using patented D MAPPS technology. They offer a wide range of innovative high quality soft tissue and wound care products for tissue regeneration.
Flexicon America is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Veritas Pharma Inc (trading symbol CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is an early stage pharmaceutical company developing innovative cannabinoid prescription medicines to treat medical conditions such as pain, emesis (nausea/vomiting), glaucoma, and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate medicines using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).